Back to results
US 12,636,417 B2Granted
Device for inline monitoring of free nucleosomes in blood
AssigneeBelgian Volition SRL
InventorJacob Vincent Micallef
Life of this patent
Estimating the term…
Abstract
The present invention relates to an extracorporeal device or an ex vivo organ perfusion device comprising an inline monitoring method or device for measuring cell free nucleosomes, particularly an apheresis device comprising a monitoring method or device for measuring cell free nucleosomes in the blood of a subject.
Claims18
An apheresis device, comprising:
- a monitoring device for measuring a level of cell free nucleosomes present in the blood of a subject, wherein the monitoring device comprises a solid phase with immobilized binding agents for binding cell free nucleosomes and wherein the monitoring device is configured to measure the level of cell free nucleosomes present in the blood of the subject in real-time.
An ex vivo organ perfusion device, comprising:
- a monitoring device for measuring a level of cell free nucleosomes present in a liquid perfusate, wherein the monitoring device comprises a solid phase with immobilized binding agents for binding cell free nucleosomes and wherein the monitoring device is configured to measure the level of cell free nucleosomes present in the blood of the subject in real-time.
A method of monitoring a subject during an apheresis procedure, comprising:
- passing blood from a subject through an extracorporeal device that comprises a monitoring device for measuring a level of cell free nucleosomes present in blood, wherein the monitoring device comprises a solid phase with immobilized binding agents for binding cell free nucleosomes;
- and
- monitoring the level of cell free nucleosomes in the blood of the subject in real-time using the monitoring device of the extracorporeal device.
A method of treating a disease in a subject in need thereof, comprising:
- passing blood from a subject through an extracorporeal device that comprises a monitoring device for measuring a level of cell free nucleosomes present in blood, wherein the monitoring device comprises a solid phase with immobilized binding agents for binding cell free nucleosomes;
- and
- monitoring the level of cell free nucleosomes in the blood of the subject in real-time using the monitoring device of the extracorporeal device.
Dependencies are inferred from the claim text.